Serum immunoreactive interleukin‐6 and C‐reactive protein levels in patients with multiple myeloma at diagnosis
- 1 February 1994
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 86 (2), 391-393
- https://doi.org/10.1111/j.1365-2141.1994.tb04748.x
Abstract
Serum bioactive but not immunoreactive interleukin-6 (IL-6), and serum C-reactive protein (CRP), have been reported to be of prognostic significance in multiple myeloma (MM). We measured serum immunoreactive IL-6 by a sensitive enzyme-linked immunosorbent assay in 30 MM patients at diagnosis. In 30% of the patients serum immunoreactive IL-6 exceeded the upper reference limit. The concentrations of CRP and IL-6 showed a linear association. Logarithmically transformed IL-6, CRP and beta 2-microglobulin were significant variables by univariate survival analysis; by multivariate analysis CRP was a slightly stronger prognostic factor than IL-6 and the only one of independent prognostic significance.Keywords
This publication has 8 references indexed in Scilit:
- Acute phase proteins and prognosis in multiple myelomaBritish Journal of Haematology, 1993
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging systemBlood, 1992
- Radioimmunoassay for the measurement of serum IL‐6 and its correlation with tumour cell mass parameters in multiple myelomaAmerican Journal of Hematology, 1992
- Interleukin-6 is a prognostic factor in multiple myeloma [letter] [see comments]Blood, 1991
- The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with MyelomaLeukemia & Lymphoma, 1991
- Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6Hepatology, 1990
- Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias.Journal of Clinical Investigation, 1989
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975